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Abstract—Outcome-driven recommendations about time intervals during which ambulatory blood pressure should be measured 
to diagnose white-coat or masked hypertension are lacking. We cross-classified 8237 untreated participants (mean age, 50.7 
years; 48.4% women) enrolled in 12 population studies, using ≥140/≥90, ≥130/≥80, ≥135/≥85, and ≥120/≥70 mm Hg as 
hypertension thresholds for conventional, 24-hour, daytime, and nighttime blood pressure. White-coat hypertension was 
hypertension on conventional measurement with ambulatory normotension, the opposite condition being masked hypertension. 
Intervals used for classification of participants were daytime, nighttime, and 24 hours, first considered separately, and next 
combined as 24 hours plus daytime or plus nighttime, or plus both. Depending on time intervals chosen, white-coat and masked 
hypertension frequencies ranged from 6.3% to 12.5% and from 9.7% to 19.6%, respectively. During 91 046 person-years, 729 
participants experienced a cardiovascular event. In multivariable analyses with normotension during all intervals of the day 
as reference, hazard ratios associated with white-coat hypertension progressively weakened considering daytime only (1.38; 
P=0.033), nighttime only (1.43; P=0.0074), 24 hours only (1.21; P=0.20), 24 hours plus daytime (1.24; P=0.18), 24 hours 
plus nighttime (1.15; P=0.39), and 24 hours plus daytime and nighttime (1.16; P=0.41). The hazard ratios comparing masked 
hypertension with normotension were all significant (P<0.0001), ranging from 1.76 to 2.03. In conclusion, identification of 
truly low-risk white-coat hypertension requires setting thresholds simultaneously to 24 hours, daytime, and nighttime blood 
pressure. Although any time interval suffices to diagnose masked hypertension, as proposed in current guidelines, full 24-hour 
recordings remain standard in clinical practice.  (Hypertension. 2014;64:935-942.) • Online Data Supplement
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Ambulatory blood pressure should be offered to those with elevated conventional blood pressure.1,2 White-coat 
hypertension is a condition, characterized by an elevated blood 
pressure on conventional office measurement, but a normal 
ambulatory blood pressure outside the medical environment. 
Conversely, masked hypertension is a normal blood pressure 
on conventional measurement accompanied by an elevated 
blood pressure on ambulatory monitoring.
To define white-coat and masked hypertension, guidelines1–5 
and previous studies6,7 have applied varying thresholds dur-
ing different periods of the day, which have included systolic/
diastolic blood pressure thresholds of ≥130/≥80 mm Hg for 
the 24-hour blood pressure, ≥135/≥85 mm Hg for the day-
time or awake blood pressure, and ≥120/≥70 mm Hg for the 
nighttime or asleep blood pressure.2,4,5 There is no firm recom-
mendation on how to maximize discrimination of risk among 
patients with white-coat and masked hypertension by applying 
the aforementioned thresholds to 24-hour, daytime, or night-
time blood pressure levels or combinations of these intervals.2 
To address this issue, we did a participant-level meta-analysis 
among 8237 people recruited from 12 populations and enrolled 
in the International Database on Ambulatory Blood Pressure 
in Relation to Cardiovascular Outcomes (IDACO). We deter-
mined the long-term outcome associated with white-coat 
hypertension and masked as defined from ambulatory blood 
pressure thresholds applied during varying periods of the day.
Methods
Study Population
Previous publications have described the construction of the IDACO 
database in detail.8 Studies qualified for inclusion if they involved a 
random population sample, if baseline information on the conven-
tional and ambulatory blood pressures and cardiovascular risk factors 
was available, and if subsequent follow-up included both fatal and 
nonfatal outcomes. All studies received ethical approval and adhered 
to the principles of the Declaration of Helsinki, and participants gave 
written informed consent.
The IDACO database8 currently includes 12 752 people represent-
ing 12 randomly recruited population cohorts9–18 with validated infor-
mation on outcome. Exclusion criteria were as follows: (1) age <18 
years (n=303), (2) conventional blood pressure unavailable (n=248), 
(3) nighttime blood pressure not recorded (n=1391),10 (4) being on 
antihypertensive drug treatment at baseline (n=2152), and (5) am-
bulatory blood pressure recordings not complying with predefined8 
quality standards, including <10 daytime or <5 nighttime readings 
(n=421). The number of participants statistically analyzed was 8237 
(Figure S1 in the online-only Data Supplement).
Cross-Classification Based on Conventional and 
Ambulatory Blood Pressure
Previous publications19,20 and the expanded Methods available in the 
online-only Data Supplement provide detailed information on conven-
tional and ambulatory blood pressure measurement and on the anthro-
pometric and biochemical measurements performed at baseline.
Conventional hypertension was a conventional blood pressure of 
140 mm Hg systolic or 90 mm Hg diastolic or more.5 Ambulatory hy-
pertension was a 24-hour level of 130 mm Hg systolic or 80 mm Hg 
diastolic or more; for the daytime blood pressure these thresholds 
were 135 and 85 mm Hg and for the nighttime blood pressure 120 
and 70 mm Hg, respectively.5 Normotension and sustained hyper-
tension were consistently normal or elevated levels on both con-
ventional and ambulatory blood pressures (Figure S2). White-coat 
hypertension was defined as conventional hypertension in the pres-
ence of a normal ambulatory blood pressure. Masked hypertension 
was defined as ambulatory hypertension in participants with a nor-
mal conventional blood pressure. When systolic or diastolic blood 
pressure was in a different category (normotensive versus hyperten-
sive), we considered the participant as hypertensive. Table S1 lists 
the thresholds and intervals used for the cross-classification of par-
ticipants. For ambulatory time intervals including nested periods (24 
hours±daytime±nighttime), the interval with the highest blood pres-
sure classification (normotensive versus hypertensive) determined the 
ambulatory blood pressure status.
Ascertainment of Events
We ascertained vital status and the incidence of fatal and nonfatal 
diseases from the appropriate sources in each country, as described 
in detail in previous publications.19,20 Outcomes were coded accord-
ing to the International Classification of Diseases (ICD). Fatal and 
nonfatal stroke (ICD-Eighth/Ninth Revsion [8/9] 430–434 and 436, 
ICD-10 I60–I64 and I67–I68) did not include transient ischemic 
attacks. Coronary events encompassed death from ischemic heart 
disease (ICD-8 411–412, ICD-9 411 and 414, and ICD-10 I20, I24–
I25), sudden death (ICD-8 427.2 and 795, ICD-9 427.5 and 798, and 
ICD-10 I46 and R96), nonfatal myocardial infarction (ICD-8/9 410 
and ICD-10 I21–I22), and coronary revascularization. Cardiac events 
comprised coronary end points and fatal and nonfatal heart failure 
(ICD-8 428, 427.1, 427.2, and 429; ICD-9 429 and ICD-10 I50 and 
J81). The diagnosis of heart failure required admission to hospital in 
the 3 cohorts.9–11 In the other cohorts, heart failure was either a clini-
cal diagnosis or the diagnosis on the death certificate. However, in 
all cases the event was validated against hospital files or records held 
by family doctors. The cardiovascular end point included all afore-
mentioned end points plus cardiovascular mortality (ICD-8 390–448, 
ICD-9 390.0–459.9, and ICD-10 I00 to I79 and R96). In all outcome 
analyses, we only considered the first event within each category.
Statistical Analysis
For database management and statistical analysis, we used SAS 
software, version 9.3 (SAS Institute Inc, Cary, NC). We compared 
mean values and proportions using the standard normal z test for 
large samples or ANOVA and the χ2-statistic, respectively. We used 
McNemar–Bowker test for the pairwise comparison of proportions. 
After stratification for cohort and sex, we interpolated missing values 
of body mass index (n=8) and total serum cholesterol (n=611) from 
the regression slope on age. In participants with unknown smoking 
(n=22), drinking (n=384), history of cardiovascular disease (n=1), or 
diabetes mellitus (n=3), we set the design variable to the cohort- and 
sex-specific mean of the codes (0, 1). Statistical significance was an 
α-level of ≤0.05 on 2-sided tests.
We calculated incidence rates in each category while standardizing 
by the direct method for sex and age (<40, 40–59, and ≥60 years). 
We used stratified Cox models to account for the heterogeneity of 
baseline hazards among cohorts and adjusted for sex, age, body mass 
index, smoking and drinking, total cholesterol, history of cardiovas-
cular disease, and diabetes mellitus. Unless otherwise indicated, we 
used normotension as the reference group (hazard ratio, 1).
Results
Baseline Characteristics
Of 8237 participants, 3986 (48.4%) were women, 2438 
(29.7%) were current smokers, 455 (5.5%) had diabetes mel-
litus, and 650 (7.9%) had a history of cardiovascular disease. 
Age averaged 50.7 (SD, 15.8) years. In all participants, the 
conventional blood pressure averaged 128.8 (21.6) mm Hg 
systolic and 78.6 (11.3) mm Hg diastolic. The corresponding 
ambulatory blood pressure levels were 122.1 (13.6) and 73.1 
(8.2) mm Hg in 24-hour, 128.5 (14.5) and 78.3 (8.9) mm Hg in 
daytime recordings, and 111.0 (14.5) and 64.0 (9.0) mm Hg in 
nighttime, respectively. The median (5th–95th percentile inter-
val) numbers of readings averaged to estimate the 24-hour, 
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daytime, and nighttime blood pressure were 55 (35–82), 28 
(15–42), and 11 (6–13), respectively.
Table 1 lists the baseline characteristics by 4 categories 
according to the cross-classification of conventional and 
24-hour ambulatory blood pressure. The differences across the 
4 categories were significant for all variables listed (P<0.0001).
Prevalence of White-Coat, Masked, and  
Sustained Hypertension
Based on the cross-classification between conventional and 
24-hour ambulatory blood pressure (Table 1), 4988 par-
ticipants (60.6%) were normotensive and 881 (10.7%), 800 
(9.7%), and 1568 (19.0%) had white-coat, masked, and sus-
tained hypertension, respectively. Using different time inter-
vals during which ambulatory blood pressure thresholds were 
applied substantially affected the estimates of prevalence 
(Table 2). They ranged from 50.7% to 60.6% for normoten-
sion, from 6.3% to 12.5% for white-coat hypertension, from 
9.7% to 19.6% for masked hypertension, and from 17.3% 
to 23.5% for sustained hypertension. The prevalence of nor-
motension and white-coat hypertension was lowest and the 
prevalence of masked and sustained hypertension was highest 
based on thresholds set simultaneously to the 24-hour and the 
daytime and nighttime blood pressures (Table 2). Table 3 sum-
marizes reclassification rates of participants with white-coat 
and masked hypertension from the commonly used definitions 
based on daytime, nighttime, or 24-hour ambulatory blood 
pressure to one of the other definitions.
Incidence of Events
In the overall study population, median follow-up was 11.1 
years (5th–95th percentile interval, 2.5–18.2 years). During 
91 046 person-years of follow-up, 906 participants died (10.0 
per 1000 person-years) and 729 participants experienced a fatal 
or nonfatal cardiovascular event (8.2 per 1000 person-years). 
Considering cause-specific first cardiovascular events, the inci-
dence of cardiac events and stroke amounted to 473 and 242, 
respectively. More details on the incidence of end points are 
available in the Results in the online-only Data Supplement.
Risk of a Cardiovascular Event Associated With 
White-Coat Hypertension
Table 4 provides risk estimates by varying time intervals dur-
ing which the ambulatory blood pressure thresholds were 
Table 1. Baseline Characteristics of 8237 Untreated Participants Cross-Classified by 
Conventional and 24-Hour Ambulatory Blood Pressure
Characteristics Normotension
White-Coat 
Hypertension
Masked 
Hypertension
Sustained 
Hypertension
No. of characteristics (%) 4988 881 800 1568
  Women 2767 (55.5) 404 (45.9)* 293 (36.6)* 522 (33.3)
  Current smoking 1544 (31.0) 168 (19.2)* 298 (37.3)* 428 (27.4)*
  Drinking alcohol 2304 (47.5) 381 (46.6) 458 (60.3)* 923 (64.6)†
  Diabetes mellitus 182 (3.6) 67 (7.6)* 57 (7.1) 149 (9.5)
  Previous cardiovascular 
diseases
237 (4.8) 126 (14.3)* 54 (6.8)* 233 (14.9)*
  Ethnicity (white) 4171 (83.6) 662 (75.3)* 641 (80.1)† 1294 (82.6)
Mean characteristic (SD)
  Age, y 45.7 (15.1) 59.3 (13.8)* 52.8 (14.0)* 60.8 (12.4)*
  Body mass index, kg/m2 24.3 (3.8) 26.0 (4.1)* 25.7 (4.0) 26.9 (4.4)*
  Total serum cholesterol, mmol/L 5.44 (1.15) 5.80 (1.26)* 5.68 (1.18)† 5.86 (1.16)*
Blood pressure
  Conventional systolic, mm Hg 117.0 (11.3) 148.4 (15.0)* 126.2 (8.9)* 156.7 (20.9)*
  Conventional diastolic, mm Hg 73.2 (7.9) 85.6 (9.4)* 78.7 (7.3)* 91.7 (10.4)*
  24-h systolic, mm Hg 114.7 (7.7) 121.4 (6.1)* 132.7 (7.7)* 140.8 (12.0)*
  24-h diastolic, mm Hg 69.3 (5.3) 71.7 (5.2)* 79.9 (5.8)* 82.6 (8.3)*
  Daytime systolic, mm Hg 121.0 (9.1) 128.0 (8.3)* 139.1 (10.0)* 147.2 (12.9)*
  Daytime diastolic, mm Hg 74.5 (6.3) 76.8 (7.0)* 84.9 (7.0)* 87.5 (9.4)*
  Nighttime systolic, mm Hg 104.1 (8.8) 109.7 (8.8)* 120.9 (10.7)* 128.8 (15.3)*
  Nighttime diastolic, mm Hg 60.2 (6.3) 62.8 (6.3)* 70.5 (7.4)* 73.4 (9.5)*
Values are number of participants (%) or arithmetic mean (SD). Thresholds for hypertension were ≥140/≥90 and 
≥130/≥80 mm Hg on conventional and 24-hour ambulatory measurement, respectively. Normotension and sustained 
hypertension were consistently normal or elevated blood pressure on both conventional and 24-hour ambulatory 
measurement. White-coat hypertension had a raised conventional blood pressure and normal 24-hour blood pressure. 
Masked hypertension had an elevated 24-hour ambulatory blood pressure with normal conventional blood pressure. 
If for a type of measurement, systolic and diastolic blood pressures were in a different category, participants were 
classified as hypertensive. Smoking, drinking, diabetes mellitus, history of cardiovascular disease, body mass index, and 
cholesterol were unavailable in 22, 384, 3, 1, 8, and 611 participants, respectively. 
Significance of the difference with the left adjacent column: *P<0.001 and †P<0.05.
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applied. Although accounting for cohort, sex, age, body mass 
index, smoking, drinking, total serum cholesterol, history of 
cardiovascular disease, and diabetes mellitus (Table 4), white-
coat hypertension based on daytime blood pressure compared 
with daytime normotension as well as that based on nighttime 
blood pressure compared with nighttime normotension car-
ried significantly elevated risks of 30% (P≤0.048). Defining 
white-coat hypertension based on the 24-hour blood pressure 
with or without accounting for the daytime or nighttime blood 
pressure or both weakened the risk compared with normoten-
sion during the same periods to a nonsignificant level ranging 
from 27% (P=0.097) for 24-hour plus daytime blood pressure 
to 9% (P=0.55) for 24-hour plus nighttime blood pressure. 
Irrespective of the ambulatory blood pressure time intervals 
used to cross-classify participants, the linear trend in the haz-
ard ratios from normotension over white-coat and masked 
hypertension to sustained hypertension was consistently sig-
nificant (P<0.0001).
In Table 4, the normotensive reference group differed 
according to the time intervals considered. In a further step of 
the analysis, we applied the most stringent definition of normo-
tension as unique reference (Figure 1). This definition required 
that the conventional blood pressure was normal and that the 
24-hour, daytime, and nighttime ambulatory blood pressures 
were within normal limits. The hazard ratios for white-coat 
hypertension versus normotension weakened from 1.38 for 
daytime only to 1.16 for 24 hours plus daytime and nighttime. 
Conversely, applying the most stringent definition of hyperten-
sion (Figure 2) showed that the risk of white-coat hyperten-
sion was consistently lower than that of sustained hypertension 
(P<0.0001) with hazard ratios decreasing from 0.57 for day-
time to 0.45 for 24 hours plus daytime and nighttime.
Risk of a Cardiovascular Event Associated With 
Masked Hypertension
In multivariable-adjusted analyses (Table 4), the risk associ-
ated with masked hypertension compared with normotension 
was always highly significant (P≤0.0001) with estimates of 
excess risk ranging from 61% to 81%. Applying the most strin-
gent definition of normotension (Figure 1) confirmed that the 
hazard ratios comparing masked hypertension with normoten-
sion were all significant (P<0.0001), between 1.76 and 2.03. 
Conversely, applying the most stringent definition of hyperten-
sion (Figure 2) showed that the risk of masked hypertension 
was lower than that of sustained hypertension (P≤0.0074). The 
hazard ratios were essentially similar, from 0.61 to 0.70.
Risk of Other End Points Associated With White-
Coat and Masked Hypertension
Results for total and cardiovascular mortality, fatal and non-
fatal cardiac events, and stroke—equivalent to those given for 
the composite cardiovascular end point in Table 4—are pro-
vided in Table S2. In analyses with normotension as reference 
and adjusted as before, white-coat hypertension did not con-
fer a formally significantly elevated risk (P≥0.051) except for 
the risk of stroke based on a nighttime-derived definition of 
white-coat hypertension (P=0.0065).
Table 3. Reclassification of White-Coat and Masked Hypertensive Participants
Time Intervals Used for 
Reclassification
White-Coat Hypertension Masked Hypertension
Original 
Intervals
Maintaining 
White-Coat 
Hypertension
Reclassified 
to Sustained 
Hypertension
Original 
Intervals
Maintaining 
Masked 
Hypertension
Reclassified to 
Normotension
From daytime to 24 h 747 642 (85.9) 105 (14.1) 1105 668 (60.5) 437 (39.5)
From nighttime to 24 h 1027 724 (70.5) 303 (29.5) 982 566 (57.6) 416 (42.4)
From daytime to 24 h plus 
daytime and nighttime
747 515 (68.9) 232 (31.1) 1105 1105 (100) 0
From nighttime to 24 h 
plus daytime and nighttime
1027 515 (50.1) 512 (49.9) 982 982 (100) 0
From 24 h to 24 h plus 
daytime and nighttime
881 515 (58.5) 366 (41.5) 800 800 (100) 0
Values are number of participants (reclassification rates, %) of white-coat and masked hypertensive participants from 
the commonly used definitions based on daytime, nighttime, or 24-hour ambulatory blood pressure to one of the other 
definitions. The McNemar–Bowker test for symmetry along the diagonal of the matrix was significant for all rows (P<0.0001).
Table 2. Prevalence of Blood Pressure Categories According 
to Intervals of Ambulatory Monitoring
Intervals Used 
to Categorize 
the Ambulatory 
Blood Pressure Normotension
White-coat 
Hypertension
Masked 
Hypertension
Sustained 
Hypertension
Daytime only 4683 (56.9) 747 (9.1) 1105 (13.4) 1702 (20.7)
Nighttime only 4806 (58.3) 1027 (12.5) 982 (11.9) 1422 (17.3)
24 h only 4988 (60.6) 881 (10.7) 800 (9.7) 1568 (19.0)
24 h plus daytime 4551 (55.3) 642 (7.8) 1237 (15.0) 1807 (21.9)
24 h plus nighttime 4572 (55.5) 724 (8.8) 1216 (14.8) 1725 (20.9)
24 h plus daytime 
and nighttime
4176 (50.7) 515 (6.3) 1612 (19.6) 1934 (23.5)
Values are number of participants (%). Normotension and sustained hyper-
tension had consistently normal or elevated blood pressure levels on both 
conventional and ambulatory measurement. White-coat hypertension was 
defined as conventional hypertension in the presence of a normal ambulatory 
blood pressure. Masked hypertension was defined as ambulatory hypertension in 
participants with a normal conventional blood pressure. When systolic or diastolic 
blood pressure was in a different category (normotensive vs hypertensive), 
participant were classified as hypertensive. For ambulatory time intervals 
including nested periods (24 hours±daytime±nighttime), the interval with the 
highest blood pressure classification (normotensive vs hypertensive) determined 
the ambulatory blood pressure status.
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Masked hypertension was a significant predictor (P≤0.023) 
of all end points with the exception of all-cause mortality if 
the diagnosis was derived from the daytime blood pressure, 
24-hour blood pressure, or 24-hour plus daytime blood pres-
sure (P≥0.059).
Discussion
Current guidelines for ambulatory blood pressure monitor-
ing or for the management of hypertension do not provide 
outcome-driven evidence for defining the time windows 
during which the ambulatory blood pressure should be mea-
sured to define white-coat and masked hypertension in an 
accurate manner. Depending on the definition, frequencies 
of white-coat and masked hypertension ranged from 6.3% to 
12.5% and from 9.7% to 19.6%, respectively. Furthermore, 
the risk associated with white-coat hypertension decreased 
when a more stringent definition of ambulatory normotension 
was used. Finally, ambulatory hypertension during any time 
interval predicted an ≈2-fold higher cardiovascular risk in 
patients with masked hypertension.
During the past decade, European guidelines5,21,22 have 
proposed changing or twin thresholds for ambulatory hyper-
tension without providing any solid justification in terms of 
outcome data. The 2003 guideline only recommended a thresh-
old for the 24-hour ambulatory blood pressure of ≥125/≥80 
mm Hg.21 The 2007 guideline proposed as thresholds for the 
24-hour, daytime, and nighttime blood pressure levels of ≥125 
to 130/≥80, ≥130 to 135/≥85, and ≥120/≥70 mm Hg, respec-
tively.22 The 2013 guideline5 removed the ambiguity in the 
thresholds for the 24-hour and daytime blood pressure, rec-
ommending ≥130/≥80 and ≥135/≥85 mm Hg, respectively, 
whereas keeping the nighttime threshold at ≥120/≥70 mm Hg. 
In a 2007 analysis of the IDACO database,6 we determined 
thresholds for the ambulatory blood pressure, which yielded 
10-year cardiovascular risks similar to those associated with 
optimal (120/80 mm Hg), normal (130/85 mm Hg), and high 
(140/90 mm Hg) blood pressure on conventional measurement. 
After rounding, approximate thresholds for an optimal ambula-
tory blood pressure amounted to 115/75 mm Hg for 24 hours, 
120/80 mm Hg for daytime, and 100/65 mm Hg for nighttime. 
Rounded thresholds for a normal ambulatory blood pressure 
were 125/75, 130/85, and 110/70 mm Hg, respectively, and 
those for ambulatory hypertension were 130/80, 140/85, and 
120/70 mm Hg.
Whether white-coat hypertension substantially elevates car-
diovascular risk continues to divide expert opinion. In a meta-
analysis of summary statistics from 4 prospective cohorts, 
the pooled hazard ratio for stroke associated with white-coat 
hypertension defined by a daytime blood pressure threshold 
of 130/80 mm Hg became comparable with that in ambula-
tory hypertension group by the ninth year of follow-up.23 
However, the median follow-up of the 4 cohorts was only 
5.4 years, and the pooled hazard ratio was not adjusted.23 The 
risk in white-coat hypertension was not significantly different 
from that in normotension when multivariable-adjusted mod-
els were applied.12,24,25 In the meta-analysis by Pierdomenico 
and Cuccurullo,25 5 of the 7 eligible studies applied a daytime 
blood pressure threshold of 135/85 mm Hg, whereas 2 other 
studies either applied a daytime threshold ranging from 131 
to 136 mm Hg26 or a 24-hour blood pressure cut off of 130/80 
mm Hg.27 In a previous IDACO publication,28 we included 
both treated and untreated participants. In this analysis, we 
classified treated people according to the achieved ambula-
tory blood pressure.28 Compared with normotension, the risk 
of all cardiovascular and cause-specific cardiovascular com-
plications was not increased, irrespective of whether we used 
130/80 or 135/85 mm Hg as cutoff threshold for the daytime 
blood pressure (0.63≥P≥0.09).28 Subsequently, Franklin et 
al,24 using the IDACO database, reported that in treated sub-
jects with isolated systolic hypertension, the cardiovascular 
risk was similar in elevated conventional and normal daytime 
systolic blood pressure as compared with those with normal 
Table 4. Risk of Cardiovascular End Point by Intervals of 
Ambulatory Monitoring
Blood Pressure  
Cross-Classification E/R, n Rate (SE)
Hazard Ratio 
(95% CI) P Value
Daytime
  Normotension 203/4683 6.0 (0.4) 1.00 ...
  White-coat hypertension 92/747 9.7 (1.2) 1.30 (1.00–1.69) 0.048
  Masked hypertension 105/1105 8.8 (0.9) 1.61 (1.27–2.05) 0.0001
  Sustained hypertension 329/1702 13.7 (0.8) 2.14 (1.76–2.60) <0.0001
Nighttime
  Normotension 209/4806 5.9 (0.4) 1.00 ...
  White-coat hypertension 121/1027 8.7 (0.9) 1.30 (1.03–1.64) 0.031
  Masked hypertension 99/982 9.6 (1.0) 1.71 (1.34–2.18) <0.0001
  Sustained hypertension 300/1422 15.4 (0.9) 2.40 (1.97–2.93) <0.0001
24 h
  Normotension 219/4988 5.9 (0.4) 1.00 ...
  White-coat hypertension 98/881 8.3 (1.0) 1.20 (0.93–1.54) 0.16
  Masked hypertension 89/800 10.1 (1.1) 1.81 (1.41–2.32) <0.0001
  Sustained hypertension 323/1568 15.0 (0.9) 2.31 (1.91–2.80) <0.0001
24 h plus daytime
  Normotension 187/4551 5.7 (0.4) 1.00 ...
  White-coat hypertension 74/642 9.0 (1.2) 1.27 (0.96–1.69) 0.097
  Masked hypertension 121/1237 9.1 (0.8) 1.72 (1.36–2.17) <0.0001
  Sustained hypertension 347/1807 13.7 (0.8) 2.23 (1.83–2.72) <0.0001
24 h plus nighttime
  Normotension 189/4572 5.7 (0.4) 1.00 ...
  White-coat hypertension 70/724 7.3 (1.1) 1.09 (0.82–1.45) 0.55
  Masked hypertension 119/1216 9.2 (0.9) 1.67 (1.32–2.11) <0.0001
  Sustained hypertension 351/1725 14.8 (0.8) 2.35 (1.93–2.87) <0.0001
24 h plus daytime and nighttime
  Normotension 159/4176 5.5 (0.5) 1.00 ...
  White-coat hypertension 50/515 7.7 (1.3) 1.13 (0.81–1.57) 0.47
  Masked hypertension 149/1612 8.8 (0.7) 1.70 (1.35–2.14) <0.0001
  Sustained hypertension 371/1934 13.8 (0.8) 2.34 (1.90–2.88) <0.0001
Definition of the blood pressure cross-classifications is given in the Methods 
and in the footnote to Table 2. Rates (SE) of events per 1000 person-year were 
standardized by the direct method for sex and age. Hazard ratios (95% CI) 
express the risk compared with normotension and were adjusted for sex, age, 
body mass index, smoking, drinking, total cholesterol, diabetes mellitus, history 
of cardiovascular disease, and cohort. CI indicates confidence interval; and E/R, 
events/participants at risk.
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conventional and normal daytime blood pressure (P=0.57). 
However, both treated patients with isolated systolic hyper-
tension and white-coat hypertension and treated participants 
with normal blood pressure had an ≈2-fold increased cardio-
vascular risk when compared with untreated normotensive 
people.24 Summarizing the evidence of previous studies,26 it 
is clear that the long-term white-coat hypertension carries an 
increased risk and that the prognostic meaning of white-coat 
hypertension differs among treated and untreated subjects. 
What our current study adds to the knowledge on white-coat 
hypertension26 is that to identify the low-risk subjects among 
untreated people with white-coat hypertension, full 24-hour 
ambulatory recordings are required and the most stringent def-
inition of ambulatory normotension, with thresholds applied 
to the whole ambulatory recording including daytime and 
nighttime, has to be applied. Although in our study the risk 
of white-coat hypertension, as defined using the most strin-
gent definition, was not significantly different from the risk in 
sustained normotension, we cannot definitely exclude that this 
definition of white-coat hypertension is not associated with 
increased risk. Further analyses in large population cohorts 
applying the same stringent definition of white-coat hyperten-
sion are needed to confirm our findings.
In contrast to white-coat hypertension,12,26,27,29–31 the current 
literature by and large supports the view that masked hyper-
tension carries a risk only slightly lower than or equal to sus-
tained hypertension,28,32 irrespective of treatment status. The 
Finn-Home Study Investigators33 are in agreement with IDACO 
findings,28 demonstrating that high-normal systolic and dia-
stolic conventional blood pressure, older age, greater body mass 
index, current smoking, and diabetes mellitus are independent 
determinants of masked hypertension. Similarly, Franklin et al32 
reported that among people not being treated for hypertension, 
the prevalence of masked hypertension, using a daytime ambu-
latory threshold of 135/85 mm Hg, was higher in diabetic than 
in nondiabetic participants (18.1% versus 13.8%). Moreover, 
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Figure 2. Risk of a cardiovascular end point associated with white-coat and masked hypertension vs stringently defined hypertension 
defined by various intervals of ambulatory monitoring. Definition of the blood pressure cross-classifications is given in the Methods and 
in the footnote to Table 2. In this analysis, we applied the most stringent definition of hypertension as unique reference in which the 
conventional blood pressure was over the threshold and that the ambulatory blood pressure was over the thresholds for 24 hours plus 
daytime and nighttime. Hazard ratios express the risk compared with hypertension and were adjusted for sex, age, body mass index, 
smoking, drinking, total cholesterol, diabetes mellitus, history of cardiovascular disease, and cohort. Horizontal bars denote the 95% 
confidence interval of the hazard ratios.
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Figure 1. Risk of a cardiovascular end point associated with white-coat and masked hypertension vs stringently defined normotension 
defined by various intervals of ambulatory monitoring. Definition of the blood pressure cross-classifications is given in the Methods and 
in the footnote to Table 2. In this analysis, we applied the most stringent definition of normotension as unique reference in which the 
conventional blood pressure was normal and that the ambulatory blood pressure was within normal limits for 24 hours plus daytime 
and nighttime. Hazard ratios express the risk compared with normotension and were adjusted for sex, age, body mass index, smoking, 
drinking, total cholesterol, diabetes mellitus, history of cardiovascular disease, and cohort. Horizontal bars denote the 95% confidence 
interval of the hazard ratios.
 by guest on December 15, 2014http://hyper.ahajournals.org/Downloaded from 
Asayama et al  White-Coat vs Masked Hypertension  941
we previously reported that masked hypertension, as diagnosed 
by ambulatory34 or home35 blood pressure monitoring, leads to 
an ≈2-fold increase in the risk of cardiovascular events or stroke 
in people with an optimal or normal conventional blood pres-
sure. What our current study adds to the knowledge on blood 
pressure is that ambulatory hypertension during any part of the 
day reliably identifies this high-risk condition.
Our current study must be interpreted within the context 
of some potential limitations. First, conventional blood pres-
sure was the average of only 2 readings obtained at a single 
examination, which might not have been sufficient to remove 
the white-coat effect. Second, we have no information on anti-
hypertensive drug treatment after the baseline visit at enrol-
ment. Third, the current IDACO participants were recruited 
from 12 geographically areas with different life styles and 
healthcare delivery systems. Study protocols and definition 
of events were cohort specific. However, we accounted for 
these differences in methodology among cohorts by including 
center as stratification variable in the Cox proportional hazard 
models. Finally, ambulatory blood pressure monitoring was 
not standardized in terms of device type and intervals between 
readings. However, using a single SAS macro ensured that the 
time-weighted mean values during all periods of the day were 
calculated identically across cohorts.
Our current study has important clinical implications and 
may inform future guidelines. From a clinical point of view, our 
findings highlight that to identify individuals at low risk of car-
diovascular complications among untreated participants with 
white-coat hypertension, full 24-hour ambulatory recordings 
are necessary with thresholds set during the whole recording 
period including daytime and nighttime. Conversely, to diag-
nose masked hypertension, ambulatory hypertension during 
any period of the day might be sufficient with a slight difference 
in the predictive accuracy. Furthermore, among 8237 untreated 
IDACO participants, 747 (9.1%) and 881 (10.7%) had white-
coat hypertension based on the 24-hour or daytime blood pres-
sure according to the current guidelines,2,5 but only 515 (6.3%) 
had the low-risk variant as defined in our current report.
Perspectives
To identify patients with white-coat hypertension with a car-
diovascular risk similar to that of normotensive people, one 
needs full 24-hour ambulatory recordings with thresholds set 
to all recording intervals, including daytime and nighttime. 
The definition in current guidelines of truly low-risk white-
coat hypertension is therefore not precise enough. To diag-
nose masked hypertension, ambulatory hypertension during 
any period of the day is sufficient with a slight difference in 
predictive accuracy. Current guidelines therefore accurately 
cover the definition of masked hypertension. The difference 
between white-coat and masked hypertension in terms of time 
intervals during which blood pressure must be monitored is 
unexpected and novel. Our findings might inform expert com-
mittees writing guidelines so that arbitrary definitions are 
replaced by outcome-driven standards.
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What Is New?
•	 In 8237 untreated participants, we generated outcome-driven propos-
als about the time intervals during which the ambulatory blood pressure 
should be measured to diagnose truly low-risk white-coat hypertension and 
masked hypertension. White-coat hypertension was hypertension on con-
ventional measurement with ambulatory normotension, the opposite condi-
tion being masked hypertension. Intervals used for classification of partici-
pants were daytime, nighttime, and 24 hours, first considered separately, 
and next combined as 24 hours plus daytime or plus nighttime or plus both.
What Is Relevant?
•	To identify patients with white-coat hypertension who have a cardiovas-
cular risk similar to that of normotensive people, one needs full 24-hour 
ambulatory recordings with thresholds set to all recording intervals, in-
cluding daytime and nighttime.
•	To diagnose masked hypertension, ambulatory hypertension during any 
period of the day is sufficient with only a slight increase in predictive 
accuracy, if the ambulatory blood pressure is consistently elevated for 
most of the day.
Summary
The difference between white-coat and masked hypertension in 
terms of time intervals during which blood pressure must be moni-
tored was unexpected. These findings might inform guidelines so 
that outcome-driven standards replace arbitrary definitions and so 
that the management of white-coat hypertension is differentiated, 
based on the time interval of blood pressure monitoring used for 
its diagnosis.
Novelty and Significance
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Expanded Methods  
Study Population  
Analyzed participants were 1823 residents from Copenhagen, Denmark;1 851 inhabitants 
from Ohasama, Japan;2 1175 subjects from Noorderkempen, Belgium;3 713 older men 
from Uppsala, Sweden;4 1188 subjects from Montevideo, Uruguay;5 299 villagers from the 
Jingning County, China;6 930 employees of the Irish Allied Bank, Dublin, Ireland;7 204 
subjects from Novosibirsk, the Russian Federation;8 133 from Pilsen, Czech Republic;9 
266 from Padova, Italy;9 244 from Kraków, Poland;9 and 411 from Maracaibo, 
Venezuela.10  Participants recruited in Kraków, Novosibirsk, Padova, and Pilsen took part 
in the European Project on Genes in Hypertension (EPOGH).9   
Blood Pressure Measurement  
Conventional blood pressure was measured by trained observers with a mercury sphyg-
momanometer,1,6,7,9 with validated auscultatory (Elquest USM-700F2) or oscillometric  
(Omron HEM-705CP5 or Dinamap 810010) devices, using the appropriate cuff size, with 
participants in the sitting1-3,5,6,8-10 or supine4 position.  Conventional blood pressure was 
the average of two consecutive readings in one occasion1-9 except in participants from 
Maracaibo,10 who were characterized  by a single reading.   
We programmed portable monitors to obtain ambulatory blood pressure readings at 30 
minute intervals throughout the whole day,2,7 or at intervals ranging from15 minutes1,10 to 
30 minutes4 during daytime and from 30 minutes1,10 to 60 minutes at night.4  The devices 
implemented an auscultatory algorithm (SunTech Accutracker II) in Uppsala4 or an oscil-
lometric technique (SpaceLabs 90202, SpaceLabs 90207, Colin ABPM 630, and Takeda 
TM-2421) in the other cohorts.1-3,5-10  
The same SAS macro processed all ambulatory recordings, which generally remained 
unedited.  The Ohasama recordings were edited sparsely according to previously pub-
lished criteria.11  Within individual subjects, we weighted the means of the ambulatory 
blood pressure by the interval between readings.  While accounting for the daily pattern of 
activities of the participants, we defined daytime as the interval ranging from 10 AM to 8 PM 
in people from Europe1,3,4,7-9 and South America,5,10 and from 8 AM h to 6 PM in those 
from Asia.2,6  The corresponding nighttime intervals ranged from midnight to 6 AM1,3-5,7-10  
and from 10 PM to 4 AM.2,6  These fixed time intervals eliminate the transition periods in the 
morning and evening when blood pressure changes rapidly, resulting in daytime and 
nighttime blood pressure levels that are within 1–2 mm Hg of the awake and asleep lev-
els.6,12   
Other Measurements  
We used the questionnaires originally administered in each cohort to obtain information on 
each participant’s medical history and smoking habits.  Body mass index was body weight 
in kilograms divided by height in meters squared.  Biochemical measurements included se-
rum cholesterol and blood glucose.  Diabetes mellitus was the use of antidiabetic drugs, a 
fasting blood glucose concentration of at least 7.0 mmol/L, a random blood glucose con-
centration of at least 11.1 mmol/L,13 a self-reported diagnosis, or diabetes documented in 
practice or hospital records.   
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Cross-Classification Based on Systolic and Diastolic Conventional and Ambulatory 
Blood Pressure  
Conventional systolic hypertension was a conventional systolic blood pressure of at least 
140 mm Hg.  Conventional diastolic hypertension was a conventional diastolic blood pres-
sure 90 mm Hg or more.  Ambulatory hypertension was a 24-h level of 130 mm Hg systolic 
and/or 80 mm Hg diastolic or more; for the daytime blood pressure these thresholds were 
135 mm Hg and/or 85 mm Hg and for the nighttime blood pressure 120 mm Hg and/or 70 
mm Hg, respectively.5  Normotension and sustained hypertension were consistently nor-
mal or elevated levels on both conventional and ambulatory blood pressures (Figure S2). 
White-coat hypertension was defined as conventional hypertension in the presence of a 
normal ambulatory blood pressure.  Masked hypertension was defined as ambulatory hy-
pertension in participants with a normal conventional blood pressure.  When systolic or di-
astolic blood pressure were in a different category (normotensive vs. hypertensive), we 
considered the participant as hypertensive.   For ambulatory time intervals including nest-
ed periods (24 hours ± daytime ± nighttime), the interval with the highest blood pressure 
classification (normotensive vs. hypertensive) determined the ambulatory blood pressure 
status.   
Sensitivity Analysis Based on Multiple Imputation  
To ascertain that the simple interpolation method used to impute missing covariates did 
not weaken or inflate the associations, we repeated the analyses using a Markov single-
chain Monte Carlo imputation model including all the covariates entered in the Cox mod-
el.14  
Supplementary Results  
Incidence of Events  
In the overall study population, median follow-up was 11.1 years (5th to 95th percentile in-
terval, 2.5 to 18.2 years).  Across cohorts, median follow-up ranged from 2.5 years (2.3 to 
2.6) in Jingning to 17.6 years (16.4 to 18.2) in Dublin.  During 91,046 person-years of fol-
low-up, 906 participants died (10.0 per 1000 person-years) and 729 experienced a fatal or 
nonfatal cardiovascular event (8.2 per 1000 person-years).  Mortality included 339 cardio-
vascular deaths.  Considering cause-specific first cardiovascular events, the incidence of 
fatal and nonfatal stroke amounted to 75 and 190, respectively.  Cardiac events consisted 
of 213 fatal and 301 nonfatal events, including 89 fatal and 141 nonfatal cases of acute 
myocardial infarction, 121 deaths from ischemic heart disease, 57 sudden deaths, 34 fatal 
and 139 nonfatal cases of heart failure, and 71 cases of surgical or percutaneous coronary 
revascularization.   
The sensitivity analysis based on the Markov single-chain Monte Carlo imputation mod-
el  did not materially change our results (Table S3).   
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Table S1.  Thresholds and Intervals Used for Cross-Classification of Participants  
   Ambulatory Blood Pressure  
Blood Pressure  
Cross-Classification   
Conventional 
Pressure  
 24-h  Day  Night  
Normotension       
Daytime  <140/<90   …  <135/<85  …  
Nighttime  <140/<90   …  ...  <120/<70  
24 hours  <140/<90   <130/<80  ...  ...  
+ Day  <140/<90   <130/<80  <135/<85  ...  
+ Night  <140/<90   <130/<80  ...  <120/<70  
+ Day + Night  <140/<90    <130/<80  <135/<85  <120/<70  
White-coat hypertension       
Daytime ≥140/≥90   ...  <135/<85  …  
Nighttime ≥140/≥90   ...  ...  <120/<70  
24 hours ≥140/≥90   <130/<80  ...  ...  
+ Day ≥140/≥90   <130/<80  <135/<85  ...  
+ Night ≥140/≥90   <130/<80  ...  <120/<70  
+ Day and Night ≥140/≥90    <130/<80  <135/<85  <120/<70  
Masked hypertension       
Daytime  <140/<90   ...  ≥135/≥85  …  
Nighttime  <140/<90   ...  ...  ≥120/≥70  
24 hours  <140/<90   ≥130/≥80  ...  ...  
+ Day  <140/<90   ≥130/≥80  ≥135/≥85  ...  
+ Night  <140/<90   ≥130/≥80  ...  ≥120/≥70  
+ Day and Night  <140/<90    ≥130/≥80  ≥135/≥85  ≥120/≥70  
Sustained hypertension       
Daytime  ≥140/≥90   ...  ≥135/≥85  …  
Nighttime  ≥140/≥90   ...  ...  ≥120/≥70  
24 hours  ≥140/≥90   ≥130/≥80  ...  ...  
+ Day  ≥140/≥90   ≥130/≥80  ≥135/≥85  ...  
+ Night  ≥140/≥90   ≥130/≥80  ...  ≥120/≥70  
+ Day and Night  ≥140/≥90    ≥130/≥80  ≥135/≥85  ≥120/≥70  
An ellipsis indicates that the time interval was not used in the cross-classification.  Numbers are blood pressure 
thresholds in mm Hg.  For normotension and white-coat hypertension, all blood pressure thresholds in a row 
should be satisfied.  For masked and sustained hypertension, the criterion for the conventional blood pressure 
should be satisfied and the ambulatory blood pressure should be elevated during at least one interval.  
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Table S2.  Risk of Fatal Endpoints and Cardiac and Cerebrovascular Events by Intervals of Ambulatory Monitoring  
(Starts)  
Blood Pressure  
Cross-Classification 
Total  
Mortality  
Cardiovascular  
Mortality  
Cardiac  
Events  Stroke  
Number of endpoints   906  339  473  242  
Daytime       
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  1.17 (0.94–1.47) 1.07 (0.72–1.59) 1.27 (0.92–1.76) 1.60 (1.00–2.58) 
Masked hypertension  1.23 (0.99–1.51) 1.66 (1.15–2.39)† 1.53 (1.12–2.08)† 1.84 (1.21–2.79)† 
Sustained hypertension  1.37 (1.15–1.62)‡ 2.06 (1.55–2.74)‡ 1.88 (1.47–2.39)‡ 3.20 (2.27–4.51)‡ 
Nighttime      
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  0.99 (0.81–1.22) 1.22 (0.86–1.73) 1.24 (0.93–1.65) 1.76 (1.17–2.65)† 
Masked hypertension  1.29 (1.04–1.59)* 1.93 (1.34–2.76)‡ 1.51 (1.10–2.06)* 1.97 (1.30–2.99)† 
Sustained hypertension  1.59 (1.34–1.89)‡ 2.38 (1.77–3.19)‡ 2.02 (1.58–2.59)‡ 3.53 (2.50–5.00)‡ 
24 hours       
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  1.00 (0.81–1.24) 1.04 (0.71–1.52) 1.12 (0.82–1.54) 1.51 (0.98–2.35) 
Masked hypertension  1.25 (0.99–1.56) 1.93 (1.32–2.81)‡ 1.73 (1.26–2.38)‡ 1.94 (1.26–2.98)† 
Sustained hypertension  1.47 (1.24–1.74)‡ 2.24 (1.69–2.97)‡ 2.05 (1.61–2.60)‡ 3.37 (2.41–4.71)‡ 
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Table S2.  Risk of Fatal Endpoints and Cardiac and Cerebrovascular Events by Intervals of Ambulatory Monitoring  
(Continues)  
 Total  Mortality  
Cardiovascular  
Mortality  
Cardiac  
Events  Stroke  
24 hours plus daytime       
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  1.11 (0.87–1.41) 1.01 (0.65–1.55) 1.24 (0.87–1.76) 1.63 (0.99–2.67) 
Masked hypertension  1.21 (0.99–1.48) 1.73 (1.22–2.47)† 1.74 (1.30–2.34)‡ 1.69 (1.12–2.55)* 
Sustained hypertension  1.39 (1.17–1.64)‡ 2.14 (1.60–2.86)‡ 2.03 (1.59–2.61)‡ 3.05 (2.16–4.31)‡ 
24 hours plus nighttime      
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension   0.87 (0.68–1.12) 0.93 (0.60–1.45) 1.05 (0.74–1.50) 1.42 (0.86–2.33) 
Masked hypertension  1.27 (1.04–1.55)* 1.99 (1.41–2.82)‡ 1.55 (1.15–2.09)† 1.88 (1.25–2.82)† 
Sustained hypertension  1.54 (1.30–1.82)‡ 2.41 (1.79–3.24)‡ 2.04 (1.59–2.61)‡ 3.49 (2.46–4.95)‡ 
24 hours plus daytime and nighttime      
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension   0.97 (0.74–1.28) 0.86 (0.51–1.44) 1.14 (0.76–1.70) 1.49 (0.83–2.65) 
Masked hypertension   1.25 (1.03–1.52)* 1.91 (1.36–2.70)‡ 1.68 (1.26–2.25)‡ 1.80 (1.20–2.69)† 
Sustained hypertension  1.46 (1.23–1.74)‡ 2.37 (1.74–3.23)‡ 2.10 (1.62–2.72)‡ 3.32 (2.30–4.78)‡ 
Definition of the blood pressure cross-classifications are given in the Methods and in the footnote to Table 2.  Hazard ratios (95% confidence interval) express the 
risk compared to normotension and were adjusted for cohort, sex, age, body mass index, smoking, drinking, total cholesterol, diabetes mellitus, and history of car-
diovascular disease.  Significance of the hazard ratios: * P<0.05; † P<0.01; and ‡ P<0.001.    
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Table S3.  Risk of Cardiovascular Endpoint by Intervals of Ambulatory Monitoring Applying 
the Markov Single-Chain Monte Carlo Imputation Method.  
Blood Pressure  
Cross-Classification  
Number  
E / R  
Rate  
(SE)  
Hazard Ratio  
(95% CI)  P  
Daytime       
Normotension  203 / 4683 6.0 (0.4) 1.00  
White-coat hypertension  92 / 747 9.7 (1.2) 1.30 (1.00–1.70) 0.048  
Masked hypertension  105 / 1105 8.8 (0.9) 1.61 (1.27–2.05) 0.0001  
Sustained hypertension   329 / 1702 13.7 (0.8) 2.13 (1.76–2.59) <0.0001  
Nighttime       
Normotension  209 / 4806 5.9 (0.4) 1.00  
White-coat hypertension   121 / 1027 8.7 (0.9) 1.30 (1.02–1.64) 0.031  
Masked hypertension   99 / 982 9.6 (1.0) 1.71 (1.34–2.18) <0.0001  
Sustained hypertension  300 / 1422 15.4 (0.9) 2.39 (1.96–2.92) <0.0001  
24 hours       
Normotension  219 / 4988 5.9 (0.4) 1.00  
White-coat hypertension   98 / 881 8.3 (1.0) 1.20 (0.93–1.54) 0.16  
Masked hypertension  89 / 800 10.1 (1.1) 1.81 (1.41–2.32) <0.0001  
Sustained hypertension  323 / 1568 15.0 (0.9) 2.30 (1.90–2.79) <0.0001  
24 hours plus daytime      
Normotension  187 / 4551 5.7 (0.4) 1.00  
White-coat hypertension  74 / 642 9.0 (1.2) 1.27 (0.96–1.69) 0.096  
Masked hypertension  121 / 1237 9.1 (0.8) 1.72 (1.36–2.17) <0.0001  
Sustained hypertension  347 / 1807 13.7 (0.8) 2.23 (1.83–2.71) <0.0001  
24 hours plus nighttime      
Normotension  189 / 4572 5.7 (0.4) 1.00  
White-coat hypertension  70 / 724 7.3 (1.1) 1.09 (0.82–1.45) 0.55  
Masked hypertension  119 / 1216 9.2 (0.9) 1.67 (1.32–2.11) <0.0001  
Sustained hypertension  351 / 1725 14.8 (0.8) 2.35 (1.92–2.86) <0.0001  
24 hours plus daytime and nighttime      
Normotension  159 / 4176 5.5 (0.5) 1.00  
White-coat hypertension  50 / 515 7.7 (1.3) 1.13 (0.81–1.57) 0.47  
Masked hypertension   149 / 1612 8.8 (0.7) 1.70 (1.35–2.14) <0.0001  
Sustained hypertension   371 / 1934 13.8 (0.8) 2.33 (1.90–2.87) <0.0001  
Number E / R indicate the number of events / participants at risk.  Definition of the blood pressure cross-classifications are 
given in the Methods and in the footnote to Table 2.  Rates (SE) of events per 1000 person-year were standardized by the 
direct method for sex and age.  Hazard ratios (95% confidence interval) express the risk compared to normotension and 
were adjusted for sex, age, body mass index, smoking, drinking, total cholesterol, diabetes, history of cardiovascular dis-
ease, and cohort.   
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Figure S1.  Flow chart of the study participants.  BP denotes blood pressure.    
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Figure S2.  Cross-classification of office and ambulatory blood pressure categories.   
Office hypertension was a blood pressure at least 140 mm Hg systolic and/or 90 mm Hg diastolic.  
Ambulatory hypertension was a 24-h level of 130 mm Hg systolic and/or 80 mm Hg diastolic or more; 
for the daytime blood pressure these thresholds were 135 mm Hg and 85 mm Hg and for the 
nighttime blood pressure 120 mm Hg and 70 mm Hg, respectively.  If for a type of blood pressure 
measurement, systolic and diastolic blood pressure were in different categories, participants were 
classified as hypertensive.   
Normotension
Masked
Hypertension
White-coat
Hypertension
Sustained
Hypertension
Ambulatory
Blood Pressure
(mm Hg)
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Expanded Methods  
Study Population  
Analyzed participants were 1823 residents from Copenhagen, Denmark;1 851 inhabitants 
from Ohasama, Japan;2 1175 subjects from Noorderkempen, Belgium;3 713 older men 
from Uppsala, Sweden;4 1188 subjects from Montevideo, Uruguay;5 299 villagers from the 
Jingning County, China;6 930 employees of the Irish Allied Bank, Dublin, Ireland;7 204 
subjects from Novosibirsk, the Russian Federation;8 133 from Pilsen, Czech Republic;9 
266 from Padova, Italy;9 244 from Kraków, Poland;9 and 411 from Maracaibo, 
Venezuela.10  Participants recruited in Kraków, Novosibirsk, Padova, and Pilsen took part 
in the European Project on Genes in Hypertension (EPOGH).9   
Blood Pressure Measurement  
Conventional blood pressure was measured by trained observers with a mercury sphyg-
momanometer,1,6,7,9 with validated auscultatory (Elquest USM-700F2) or oscillometric  
(Omron HEM-705CP5 or Dinamap 810010) devices, using the appropriate cuff size, with 
participants in the sitting1-3,5,6,8-10 or supine4 position.  Conventional blood pressure was 
the average of two consecutive readings in one occasion1-9 except in participants from 
Maracaibo,10 who were characterized  by a single reading.   
We programmed portable monitors to obtain ambulatory blood pressure readings at 30 
minute intervals throughout the whole day,2,7 or at intervals ranging from15 minutes1,10 to 
30 minutes4 during daytime and from 30 minutes1,10 to 60 minutes at night.4  The devices 
implemented an auscultatory algorithm (SunTech Accutracker II) in Uppsala4 or an oscil-
lometric technique (SpaceLabs 90202, SpaceLabs 90207, Colin ABPM 630, and Takeda 
TM-2421) in the other cohorts.1-3,5-10  
The same SAS macro processed all ambulatory recordings, which generally remained 
unedited.  The Ohasama recordings were edited sparsely according to previously pub-
lished criteria.11  Within individual subjects, we weighted the means of the ambulatory 
blood pressure by the interval between readings.  While accounting for the daily pattern of 
activities of the participants, we defined daytime as the interval ranging from 10 AM to 8 PM 
in people from Europe1,3,4,7-9 and South America,5,10 and from 8 AM h to 6 PM in those 
from Asia.2,6  The corresponding nighttime intervals ranged from midnight to 6 AM1,3-5,7-10  
and from 10 PM to 4 AM.2,6  These fixed time intervals eliminate the transition periods in the 
morning and evening when blood pressure changes rapidly, resulting in daytime and 
nighttime blood pressure levels that are within 1–2 mm Hg of the awake and asleep lev-
els.6,12   
Other Measurements  
We used the questionnaires originally administered in each cohort to obtain information on 
each participant’s medical history and smoking habits.  Body mass index was body weight 
in kilograms divided by height in meters squared.  Biochemical measurements included se-
rum cholesterol and blood glucose.  Diabetes mellitus was the use of antidiabetic drugs, a 
fasting blood glucose concentration of at least 7.0 mmol/L, a random blood glucose con-
centration of at least 11.1 mmol/L,13 a self-reported diagnosis, or diabetes documented in 
practice or hospital records.   
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Cross-Classification Based on Systolic and Diastolic Conventional and Ambulatory 
Blood Pressure  
Conventional systolic hypertension was a conventional systolic blood pressure of at least 
140 mm Hg.  Conventional diastolic hypertension was a conventional diastolic blood pres-
sure 90 mm Hg or more.  Ambulatory hypertension was a 24-h level of 130 mm Hg systolic 
and/or 80 mm Hg diastolic or more; for the daytime blood pressure these thresholds were 
135 mm Hg and/or 85 mm Hg and for the nighttime blood pressure 120 mm Hg and/or 70 
mm Hg, respectively.5  Normotension and sustained hypertension were consistently nor-
mal or elevated levels on both conventional and ambulatory blood pressures (Figure S2). 
White-coat hypertension was defined as conventional hypertension in the presence of a 
normal ambulatory blood pressure.  Masked hypertension was defined as ambulatory hy-
pertension in participants with a normal conventional blood pressure.  When systolic or di-
astolic blood pressure were in a different category (normotensive vs. hypertensive), we 
considered the participant as hypertensive.   For ambulatory time intervals including nest-
ed periods (24 hours ± daytime ± nighttime), the interval with the highest blood pressure 
classification (normotensive vs. hypertensive) determined the ambulatory blood pressure 
status.   
Sensitivity Analysis Based on Multiple Imputation  
To ascertain that the simple interpolation method used to impute missing covariates did 
not weaken or inflate the associations, we repeated the analyses using a Markov single-
chain Monte Carlo imputation model including all the covariates entered in the Cox mod-
el.14  
Supplementary Results  
Incidence of Events  
In the overall study population, median follow-up was 11.1 years (5th to 95th percentile in-
terval, 2.5 to 18.2 years).  Across cohorts, median follow-up ranged from 2.5 years (2.3 to 
2.6) in Jingning to 17.6 years (16.4 to 18.2) in Dublin.  During 91,046 person-years of fol-
low-up, 906 participants died (10.0 per 1000 person-years) and 729 experienced a fatal or 
nonfatal cardiovascular event (8.2 per 1000 person-years).  Mortality included 339 cardio-
vascular deaths.  Considering cause-specific first cardiovascular events, the incidence of 
fatal and nonfatal stroke amounted to 75 and 190, respectively.  Cardiac events consisted 
of 213 fatal and 301 nonfatal events, including 89 fatal and 141 nonfatal cases of acute 
myocardial infarction, 121 deaths from ischemic heart disease, 57 sudden deaths, 34 fatal 
and 139 nonfatal cases of heart failure, and 71 cases of surgical or percutaneous coronary 
revascularization.   
The sensitivity analysis based on the Markov single-chain Monte Carlo imputation mod-
el  did not materially change our results (Table S3).   
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Table S1.  Thresholds and Intervals Used for Cross-Classification of Participants  
   Ambulatory Blood Pressure  
Blood Pressure  
Cross-Classification   
Conventional 
Pressure  
 24-h  Day  Night  
Normotension       
Daytime  <140/<90   …  <135/<85  …  
Nighttime  <140/<90   …  ...  <120/<70  
24 hours  <140/<90   <130/<80  ...  ...  
+ Day  <140/<90   <130/<80  <135/<85  ...  
+ Night  <140/<90   <130/<80  ...  <120/<70  
+ Day + Night  <140/<90    <130/<80  <135/<85  <120/<70  
White-coat hypertension       
Daytime ≥140/≥90   ...  <135/<85  …  
Nighttime ≥140/≥90   ...  ...  <120/<70  
24 hours ≥140/≥90   <130/<80  ...  ...  
+ Day ≥140/≥90   <130/<80  <135/<85  ...  
+ Night ≥140/≥90   <130/<80  ...  <120/<70  
+ Day and Night ≥140/≥90    <130/<80  <135/<85  <120/<70  
Masked hypertension       
Daytime  <140/<90   ...  ≥135/≥85  …  
Nighttime  <140/<90   ...  ...  ≥120/≥70  
24 hours  <140/<90   ≥130/≥80  ...  ...  
+ Day  <140/<90   ≥130/≥80  ≥135/≥85  ...  
+ Night  <140/<90   ≥130/≥80  ...  ≥120/≥70  
+ Day and Night  <140/<90    ≥130/≥80  ≥135/≥85  ≥120/≥70  
Sustained hypertension       
Daytime  ≥140/≥90   ...  ≥135/≥85  …  
Nighttime  ≥140/≥90   ...  ...  ≥120/≥70  
24 hours  ≥140/≥90   ≥130/≥80  ...  ...  
+ Day  ≥140/≥90   ≥130/≥80  ≥135/≥85  ...  
+ Night  ≥140/≥90   ≥130/≥80  ...  ≥120/≥70  
+ Day and Night  ≥140/≥90    ≥130/≥80  ≥135/≥85  ≥120/≥70  
An ellipsis indicates that the time interval was not used in the cross-classification.  Numbers are blood pressure 
thresholds in mm Hg.  For normotension and white-coat hypertension, all blood pressure thresholds in a row 
should be satisfied.  For masked and sustained hypertension, the criterion for the conventional blood pressure 
should be satisfied and the ambulatory blood pressure should be elevated during at least one interval.  
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Table S2.  Risk of Fatal Endpoints and Cardiac and Cerebrovascular Events by Intervals of Ambulatory Monitoring  
(Starts)  
Blood Pressure  
Cross-Classification 
Total  
Mortality  
Cardiovascular  
Mortality  
Cardiac  
Events  Stroke  
Number of endpoints   906  339  473  242  
Daytime       
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  1.17 (0.94–1.47) 1.07 (0.72–1.59) 1.27 (0.92–1.76) 1.60 (1.00–2.58) 
Masked hypertension  1.23 (0.99–1.51) 1.66 (1.15–2.39)† 1.53 (1.12–2.08)† 1.84 (1.21–2.79)† 
Sustained hypertension  1.37 (1.15–1.62)‡ 2.06 (1.55–2.74)‡ 1.88 (1.47–2.39)‡ 3.20 (2.27–4.51)‡ 
Nighttime      
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  0.99 (0.81–1.22) 1.22 (0.86–1.73) 1.24 (0.93–1.65) 1.76 (1.17–2.65)† 
Masked hypertension  1.29 (1.04–1.59)* 1.93 (1.34–2.76)‡ 1.51 (1.10–2.06)* 1.97 (1.30–2.99)† 
Sustained hypertension  1.59 (1.34–1.89)‡ 2.38 (1.77–3.19)‡ 2.02 (1.58–2.59)‡ 3.53 (2.50–5.00)‡ 
24 hours       
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  1.00 (0.81–1.24) 1.04 (0.71–1.52) 1.12 (0.82–1.54) 1.51 (0.98–2.35) 
Masked hypertension  1.25 (0.99–1.56) 1.93 (1.32–2.81)‡ 1.73 (1.26–2.38)‡ 1.94 (1.26–2.98)† 
Sustained hypertension  1.47 (1.24–1.74)‡ 2.24 (1.69–2.97)‡ 2.05 (1.61–2.60)‡ 3.37 (2.41–4.71)‡ 
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Table S2.  Risk of Fatal Endpoints and Cardiac and Cerebrovascular Events by Intervals of Ambulatory Monitoring  
(Continues)  
 Total  Mortality  
Cardiovascular  
Mortality  
Cardiac  
Events  Stroke  
24 hours plus daytime       
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension  1.11 (0.87–1.41) 1.01 (0.65–1.55) 1.24 (0.87–1.76) 1.63 (0.99–2.67) 
Masked hypertension  1.21 (0.99–1.48) 1.73 (1.22–2.47)† 1.74 (1.30–2.34)‡ 1.69 (1.12–2.55)* 
Sustained hypertension  1.39 (1.17–1.64)‡ 2.14 (1.60–2.86)‡ 2.03 (1.59–2.61)‡ 3.05 (2.16–4.31)‡ 
24 hours plus nighttime      
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension   0.87 (0.68–1.12) 0.93 (0.60–1.45) 1.05 (0.74–1.50) 1.42 (0.86–2.33) 
Masked hypertension  1.27 (1.04–1.55)* 1.99 (1.41–2.82)‡ 1.55 (1.15–2.09)† 1.88 (1.25–2.82)† 
Sustained hypertension  1.54 (1.30–1.82)‡ 2.41 (1.79–3.24)‡ 2.04 (1.59–2.61)‡ 3.49 (2.46–4.95)‡ 
24 hours plus daytime and nighttime      
Normotension  1.00  1.00  1.00  1.00  
White-coat hypertension   0.97 (0.74–1.28) 0.86 (0.51–1.44) 1.14 (0.76–1.70) 1.49 (0.83–2.65) 
Masked hypertension   1.25 (1.03–1.52)* 1.91 (1.36–2.70)‡ 1.68 (1.26–2.25)‡ 1.80 (1.20–2.69)† 
Sustained hypertension  1.46 (1.23–1.74)‡ 2.37 (1.74–3.23)‡ 2.10 (1.62–2.72)‡ 3.32 (2.30–4.78)‡ 
Definition of the blood pressure cross-classifications are given in the Methods and in the footnote to Table 2.  Hazard ratios (95% confidence interval) express the 
risk compared to normotension and were adjusted for cohort, sex, age, body mass index, smoking, drinking, total cholesterol, diabetes mellitus, and history of car-
diovascular disease.  Significance of the hazard ratios: * P<0.05; † P<0.01; and ‡ P<0.001.    
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Table S3.  Risk of Cardiovascular Endpoint by Intervals of Ambulatory Monitoring Applying 
the Markov Single-Chain Monte Carlo Imputation Method.  
Blood Pressure  
Cross-Classification  
Number  
E / R  
Rate  
(SE)  
Hazard Ratio  
(95% CI)  P  
Daytime       
Normotension  203 / 4683 6.0 (0.4) 1.00  
White-coat hypertension  92 / 747 9.7 (1.2) 1.30 (1.00–1.70) 0.048  
Masked hypertension  105 / 1105 8.8 (0.9) 1.61 (1.27–2.05) 0.0001  
Sustained hypertension   329 / 1702 13.7 (0.8) 2.13 (1.76–2.59) <0.0001  
Nighttime       
Normotension  209 / 4806 5.9 (0.4) 1.00  
White-coat hypertension   121 / 1027 8.7 (0.9) 1.30 (1.02–1.64) 0.031  
Masked hypertension   99 / 982 9.6 (1.0) 1.71 (1.34–2.18) <0.0001  
Sustained hypertension  300 / 1422 15.4 (0.9) 2.39 (1.96–2.92) <0.0001  
24 hours       
Normotension  219 / 4988 5.9 (0.4) 1.00  
White-coat hypertension   98 / 881 8.3 (1.0) 1.20 (0.93–1.54) 0.16  
Masked hypertension  89 / 800 10.1 (1.1) 1.81 (1.41–2.32) <0.0001  
Sustained hypertension  323 / 1568 15.0 (0.9) 2.30 (1.90–2.79) <0.0001  
24 hours plus daytime      
Normotension  187 / 4551 5.7 (0.4) 1.00  
White-coat hypertension  74 / 642 9.0 (1.2) 1.27 (0.96–1.69) 0.096  
Masked hypertension  121 / 1237 9.1 (0.8) 1.72 (1.36–2.17) <0.0001  
Sustained hypertension  347 / 1807 13.7 (0.8) 2.23 (1.83–2.71) <0.0001  
24 hours plus nighttime      
Normotension  189 / 4572 5.7 (0.4) 1.00  
White-coat hypertension  70 / 724 7.3 (1.1) 1.09 (0.82–1.45) 0.55  
Masked hypertension  119 / 1216 9.2 (0.9) 1.67 (1.32–2.11) <0.0001  
Sustained hypertension  351 / 1725 14.8 (0.8) 2.35 (1.92–2.86) <0.0001  
24 hours plus daytime and nighttime      
Normotension  159 / 4176 5.5 (0.5) 1.00  
White-coat hypertension  50 / 515 7.7 (1.3) 1.13 (0.81–1.57) 0.47  
Masked hypertension   149 / 1612 8.8 (0.7) 1.70 (1.35–2.14) <0.0001  
Sustained hypertension   371 / 1934 13.8 (0.8) 2.33 (1.90–2.87) <0.0001  
Number E / R indicate the number of events / participants at risk.  Definition of the blood pressure cross-classifications are 
given in the Methods and in the footnote to Table 2.  Rates (SE) of events per 1000 person-year were standardized by the 
direct method for sex and age.  Hazard ratios (95% confidence interval) express the risk compared to normotension and 
were adjusted for sex, age, body mass index, smoking, drinking, total cholesterol, diabetes, history of cardiovascular dis-
ease, and cohort.   
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12752 IDACO participants
8237 analyzed
303
421
248
1391
<18 years
ambulatory recording not meeting
quality standards
conventional BP not on file
nighttime BP not recorded
4515 excluded
2152 antihypertensive drug treatment
 
 
Figure S1.  Flow chart of the study participants.  BP denotes blood pressure.    
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Figure S2.  Cross-classification of office and ambulatory blood pressure categories.   
Office hypertension was a blood pressure at least 140 mm Hg systolic and/or 90 mm Hg diastolic.  
Ambulatory hypertension was a 24-h level of 130 mm Hg systolic and/or 80 mm Hg diastolic or more; 
for the daytime blood pressure these thresholds were 135 mm Hg and 85 mm Hg and for the 
nighttime blood pressure 120 mm Hg and 70 mm Hg, respectively.  If for a type of blood pressure 
measurement, systolic and diastolic blood pressure were in different categories, participants were 
classified as hypertensive.   
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